These innovative compounds represent a significant leap in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://safiyatukn002001.blogsvila.com/39434897/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide